<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609775</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-111</org_study_id>
    <nct_id>NCT03609775</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">October 9, 2018</completion_date>
  <primary_completion_date type="Actual">October 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-dummy, four-way crossover study design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change from baseline for smooth pursuit (%) to assess eye movement coordination and attention</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline for adaptive tracking (%) to assess visuo-motor control and vigilance</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline for body sway (antero-posterior in mm / 2 min) to assess postural stability</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline for visual analog scales (VAS) Bond &amp; Lader to assess subjective alertness, mood, and calmness</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline for VAS for alcohol intoxication to assess subjective effects of ethanol</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ACT-541468 PK endpoints for treatments A and B: Area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24)</measure>
    <time_frame>Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ACT-541468 PK endpoints for treatments A and B: AUC from zero to infinity (AUC0-∞)</measure>
    <time_frame>Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ACT-541468 PK endpoints for treatments A and B: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ACT-541468 PK endpoints for treatments A and B: Time to reach Cmax (tmax)</measure>
    <time_frame>Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ACT-541468 PK endpoints for treatments A and B: Terminal elimination half-life (t½)</measure>
    <time_frame>Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ethanol PK endpoints for treatments A and C: Breath ethanol concentrations (BrEC)</measure>
    <time_frame>Several timepoints on Day 1; for up to 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ethanol PK endpoints for treatments A and C: Total ethanol dose (in grams) required to maintain the 0.6 g/L ethanol clamp</measure>
    <time_frame>Several timepoints on Day 1; for up to 5 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Treatment-emergent AEs from study treatment administration up to EOT in each treatment period</measure>
    <time_frame>AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints: Treatment-emergent SAEs from study treatment administration up to EOT in each treatment period</measure>
    <time_frame>SAEs from Screening to Safety follow up; for up to 14 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A (ethanol + ACT-541468)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (ethanol placebo + ACT-541468)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C (ethanol + ACT-541468 placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D (ethanol placebo + ACT-541468 placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468</intervention_name>
    <description>One tablet of 50 mg ACT-541468 will be administered orally.</description>
    <arm_group_label>Treatment A (ethanol + ACT-541468)</arm_group_label>
    <arm_group_label>Treatment B (ethanol placebo + ACT-541468)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACT-541468 placebo</intervention_name>
    <description>Matching ACT-541468 placebo will be administered orally as 1 tablet.</description>
    <arm_group_label>Treatment C (ethanol + ACT-541468 placebo)</arm_group_label>
    <arm_group_label>Treatment D (ethanol placebo + ACT-541468 placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol 10%</intervention_name>
    <description>Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.</description>
    <arm_group_label>Treatment A (ethanol + ACT-541468)</arm_group_label>
    <arm_group_label>Treatment C (ethanol + ACT-541468 placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ethanol placebo</intervention_name>
    <description>Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.</description>
    <arm_group_label>Treatment B (ethanol placebo + ACT-541468)</arm_group_label>
    <arm_group_label>Treatment D (ethanol placebo + ACT-541468 placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Healthy male and female subjects aged between 18 and 45 years (inclusive) at
             screening.

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and a negative urine pregnancy test on Day 1 pre-dose of each treatment period. They
             must consistently and correctly use a reliable method of contraception, be sexually
             inactive, or have a vasectomized partner.

          -  Women of non-childbearing potential (i.e., postmenopausal).

          -  Body mass index of 18.0 to 32.0 kg/m2 (inclusive) at screening.

          -  Healthy on the basis of medical history, physical examination, cardiovascular
             assessments and serology and laboratory tests.

          -  Previous experience with alcohol consumption and, therefore, familiar with the effects
             of alcohol.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol.

          -  Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.

          -  Nicotine intake within 3 months prior to screening and inability to refrain from
             nicotine intake from screening until End-of-Study (EOS).

          -  Previous treatment with any prescribed medications (including vaccines) or
             over-the-counter (OTC) medications (including herbal medicines such as St John's Wort,
             homeopathic preparations, vitamins, and minerals) within 2 weeks prior to first study
             treatment administration.

          -  History or clinical evidence of alcoholism or drug abuse.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of more than 21 units or an average daily intake of more than 3
             units (males), or defined as an average weekly intake of more than 14 units or an
             average daily intake of more than 2 units (females).

          -  Individuals of Asian descent or other individuals reporting ethanol intolerance.

          -  Modified Swiss Narcolepsy Scale total score &lt; 0 at screening or history of narcolepsy
             or cataplexy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Gasser</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre For Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

